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SUMMARY
Induced pluripotent stem cells (iPSCs) can serve as a source of cardiomyocytes (CMs) to treat end-stage heart failure; however, transplan-
tation of genetically dissimilar iPSCs even within species (allogeneic) can induce immune rejection. We hypothesized that this might be
limited by matching the major histocompatibility complex (MHC) antigens between the donor and the recipient. We therefore trans-
planted fluorescence-labeled (GFP) iPSC-CMs donated from amacaque with homozygous MHC haplotypes into the subcutaneous tissue
and hearts of macaques having heterozygous MHC haplotypes (MHC-matched; group I) or without identical MHC alleles (group II) in
conjunctionwith immune suppression.Group I displayed a higherGFP intensity and less immune-cell infiltration in the graft than group
II. However, MHC-matched transplantation with single or no immune-suppressive drugs still induced a substantial host immune
response to the graft. Thus, the immunogenicity of allogeneic iPSC-CMs was reduced by MHC-matched transplantation although a
requirement for appropriate immune suppression was retained for successful engraftment.
INTRODUCTION
End-stage heart failure is generally characterized by an
insufficient number of functional cardiomyocytes (CMs)
(Towbin and Bowles, 2002). At this critical stage, cell trans-
plantation is a promising approach for increasing the num-
ber of functional CMs. Thus, transplantation with induced
pluripotent stem cells (iPSCs) represents a promising treat-
ment for this condition (Yoshida and Yamanaka, 2010,
2011); accordingly, various studies have examined the po-
tential application of iPSCs for cell transplantation therapy
in the heart (Higuchi et al., 2015; Kawamura et al., 2012;
Miki et al., 2012).
Cell transplantation therapy using iPSCs theoretically
enables autologous transplantation, which could elimi-
nate the need for immunosuppression and avoid related
problems such as malignancy and infection. However,
the clinical application of this approach is limited by safety
concerns and high costs. To overcome the former limita-
tion, banked iPSCs, in which safety has been established
in advance, are under development with the aim of
transplanting iPSC derivatives in an allogeneic fashion.
However, this approach would inevitably induce the host
immune response, limiting its therapeutic efficacy in turn.
Several approaches exist to prevent allogeneic cell trans-
plantation-related immune rejection. One is immune sup-
pression therapy using a combination of several different
types of immunosuppressants. Others are the use of major
histocompatibility complex (MHC)-matched donor cells
to reduce immunogenicity, or the suppression of MHC
expression via genetic modification. MHCmolecules func-
tion by binding to pathogen-derived peptide fragments
and displaying them on their cell surface for T cell recogni-
tion; this process is affected by the high polymorphism
of MHC genes. The recognition of non-self MHC mole-
cules causes the rejection of allogeneic organs and tissues
(Janeway et al., 2001); therefore, donor/recipient MHC
matching can decrease the rate of rejection in organ trans-
plantation (Flomenberg et al., 2004). For these approaches,
the establishment of iPSC lines from healthy donors with
homozygous MHC alleles is useful for minimizing the
number of banked iPSC lines (Nakatsuji et al., 2008; Taylor
et al., 2012).
The cynomolgus macaque is a non-human primate
that is taxonomically more closely related to humans
than other experimental primates. Cynomolgus ma-
caques have a nearly identical genomic organization of
the MHC region and drug metabolizing capacity similar
to that of humans (Kita et al., 2009; Sano et al., 2006),
thus making them a good model for organ transplanta-
tion and immunogenicity studies. At least 15 homozy-
gous or semi-homozygous haplotypes (HT1–15) have
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been identified in a Philippines macaque population
(Shiina et al., 2015), with the most frequent haplotype,
HT1, detected in 5%–10%.
In this study, we aimed to investigate the possibility of
MHC-matched transplantation using this unique colony
of primates, available through Ina Research Inc.. We hy-
pothesized that iPSC-derived CMs (iPSC-CMs) with homo-
zygousMHChaplotypesmight prevent allogeneic immune
rejection during MHC-matched transplantation.
RESULTS
MHC Genotyping
The results of MHC genotyping of iPSCs and seven ma-
caque recipients are described in Table S1. The original
macaque supplying the iPSCs expressed only one allele
at all MHC gene loci except for the minor allele of
A8*01:01, indicating that it carried a semi-homozygous
MHC haplotype (termed HT1). Four macaques (nos. 1,
2, 6, and 7) carried all alleles constituting the HT1 haplo-
type and were used as MHC-matched recipients. In
contrast, animals 3, 4, and 5 had no major HT1 haplotype
alleles; these were used as MHC-mismatched recipients
(Figure 1A).
Generation of iPSC-CMs
Undifferentiated macaque iPSCs expressed OCT4, TRA-1-
60, and SSEA-4 (Figure S1A) and were differentiated to
CMs under a protocol using human cytokines and chemi-
cals (Figure 2A), which expressed CM marker genes with
decreased OCT4 expression (Figure 2B). Nearly all of the
aggregates showed self-beating (Movie S1) at day 10 and
exhibited 80% purity of troponin T, a actinin, and GFP-
positive iPSC-CMs (Figures 2C and S1B).
The iPSC-CMs were seeded on temperature-responsive
six-well dishes, and iPSC-CM sheets were collected at
room temperature just before transplantation. The iPSC-
CM sheet showed self-beating (Movie S2) and all cells
therein expressed GFP (Figure 2I); approximately half of
these cells expressed myosin light chain (MYL; Figure 2H)
or myosin heavy chain (MYH; Figure 2I) as a CM marker.
Flow cytometry indicated that 50% ± 3% of the cell sheet
population was positive for cardiac troponin T and 46% ±
6% was positive for vimentin (n = 5) (Figures 2K and
S1C), whereas CD31- or CD144-positive cells were rarely
identified (Figure S1C). In addition, the vimentin-positive
cells were located on the lower side of the cell sheet, which
had attached to the dish (Figure 2J).
Reduced Expression of MHC Genes in iPSC-CMs
The expression of MHC class I genes in the iPSCs and
after cardiomyogenic differentiation were relatively lower
compared with peripheral blood, although they were
significantly increased following in vitro interferon-g
(IFN-g) stimulation (Figure 2D). Mafa-E (MHC-E) expres-
sion was lowest among MHC class I genes (Figure 2E) and
MHC class II genes were not expressed at any day of dif-
ferentiation even following IFN-g stimulation (data not
shown).
Engraftment of iPSC-CMs inMHC-Matched Recipients
We first subcutaneously transplanted iPSC-CMs sheets
into animals 1, 3, 6, and 7 to evaluate iPSC-CM sheet
engraftment by quantitative GFP fluorescence evaluation
at 2 weeks, 1 month, and 2 months after the transplanta-
tion (Figure 3A). GFP fluorescence could be detected in all
groups at 2 weeks and 1 month. However, the fluorescence
intensity was higher in HT1 heterozygous macaques
treated with tacrolimus (TAC), mycophenolate mofetil
(MMF), and prednisolone (PSL) (group I) than in the other
groups at 1 month (Figure 3B). GFP fluorescence could
not be detected at 2 months in recipient 3, which con-
tained no HT1 alleles and was treated with TAC, MMF,
and PSL (group II), or in HT1 heterozygous macaques
treated with TAC only (group III) and untreated HT1 het-
erozygous macaques (group IV).
We next transplanted iPSC-CMs into the heart on
the same day but prior to the subcutaneous transplan-
tation in animals 2, 4, and 5 to investigate the engraft-
ment of iPSC-CMs in the heart. The GFP fluorescence
intensity in the subcutaneously transplanted graft of
animal 2 at 1 or 2 months was higher than that of animal
4 or 5 (Figure 3A). The iPSC-CMs injected into the heart
could be detected as GFP-positive cells in recipient 2
(group I) 2 months after the transplantation, but not
in recipients 4 and 5 (group II) (Figures S2 and S3). The
cells double-positive for GFP and MYH could be de-
tected in recipient 2, although the number was limited
(Figure S3).
Immunological Rejection of iPSC-CMs
To investigate the immunological rejection of trans-
planted iPSC-CMs, we histologically compared the subcu-
taneously transplanted iPSC-CMs (Figure 4) and quantified
antibodies against iPSC-CMs in the serum at 1 month
after transplantation (Figures S1F–S1I). Although serum
levels of immunoglobulin M (IgM) or immunoglobulin G
(IgG) against iPSC-CMs were not significantly increased
compared with those at day 0, relatively severe infiltration
of lymphocytes in the graft was histologically observed
for all groups except group I. In detail, diffuse severe
lymphocyte infiltration in nearly all parts of the grafts
was observed in animals 3 and 7, and relatively localized
severe infiltration around the vessels in the graft was
observed in animals 4–6. On the other hand, in group I,
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Figure 1. Subcutaneous Transplantation of an iPSC-CM Sheet into Cynomolgus Macaques
(A) Transplantation schema of HT1 homozygous (homo) iPSC-CMs.
(B–D) Schema of subcutaneous transplantation of iPSC-CM sheets into the backs of recipient macaques. Hetero, heterozygous.
(E) Observation of transplanted iPSC-CM sheets expressing GFP.
(F) Follow-up examinations after iPSC-CM sheet transplantation.
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localized and relatively mild lymphocyte infiltration
around the graft vessels was observed in animal 1, and
almost none in animal 2. Semi-quantitative scoring for
the number of CD3- or CD4-positive cells in the graft
showed significantly lower numbers in the grafts of group
I (CD3, 1,014/mm2; CD4, 531/mm2) compared with
those of group II (CD3, 6,375/mm2; CD4, 3,950/mm2),
whereas the values for group III (CD3, 5,810/mm2;
CD4, 4,526/mm2) or group IV (CD3, 8,622/mm2; CD4,
3,805/mm2) were markedly higher (Figures 4B and S1D).
Furthermore, the expression of interleukin-2 receptor
(IL-2R) was decreased in group I grafts compared with the
other groups (Figure S1E).
Natural Killer Cell-Related Rejection of iPSC-CMs
The low expression of MHC class I genes, including
MHC-E in iPSC-CMs (Figure 2E) might cause natural
killer (NK) cell-related immune reactions because HLA-E
inhibits the cytotoxic activity of NK cells (Janeway
et al., 2001). Therefore, we examined the number of
NK cells in the subcutaneously transplanted iPSC-CMs
by quantifying the expression of NK cell markers, i.e.,
immunoglobulin gamma Fc region receptor III (FcgR
III) and natural killer group 2, member D (NKG2D). Their
expression levels were increased in macaques not treated
with immunosuppressants (group IV) or treated with
TAC only (group III) compared with HT1 heterozygous
Figure 2. Generation of Cynomolgus Ma-
caque iPSC-CM Sheets
(A) Cardiomyogenic differentiation proto-
col and the generation of iPSC-CM sheets.
(B) Expression of NKX2.5, MYH, TNT, and
OCT4 transcripts in iPSCs on days 0, 3, 7,
and 10 as analyzed by real-time PCR. Results
are relative to those at day 0 and are ex-
pressed as the means ±SD (n = 3 indepen-
dent experiments).
(C) Representative flow cytometry data
of iPSC-CMs at day 10, stained with anti-
troponin T antibodies or the isotype control.
(D) Expression of MHC class I genes in iPSCs
on days 0, 3, 7, 10, and 12 with or without
IFN-g stimulation as analyzed by real-time
PCR. Results are relative to those of the
peripheral blood and are expressed as the
means ±SD (n = 3 independent experi-
ments). *p < 0.05.
(E) Expression of MHC class I genes in iPSCs
on days 0, 3, 7, and 10 as analyzed by real-
timePCR.Mafa-A,B, F, E, and I are theMHC-A,
B, F, E, and I genes, respectively, in cyn-
omolgusmacaques. The relative quantities of
each allele are compared with those of the
peripheral blood and are expressed as the
means±SD (n = 3 independent experiments).
(F) Macaque iPSC-CM sheets in a 10-cm dish.
(G) H&E staining of the iPSC-CM sheet.
Scale bar, 100 mm.
(H) Immunohistochemistry of MYL in the
iPSC-CM sheet. Scale bar, 100 mm.
(I) Immunohistochemistry of GFP (Alexa
Fluor 488), MYH (Alexa Fluor 546), and DAPI
in the iPSC-CM sheet. Scale bar, 30 mm.
(J) Immunohistochemistry of TNT (Alexa
Fluor 488), vimentin (Alexa Fluor 546), and
DAPI in the iPSC-CM sheet. Scale bar,
30 mm.
(K) Percentage of TNT- and vimentin-positive cells in the iPSC-CM sheet as analyzed by flow cytometry (representative data are shown in
Figure S1C). Results are expressed as the means ±SD (n = 5 independent experiments).
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macaques treated with TAC, MMF, and PSL (group I)
(Figure S1E).
DISCUSSION
In this study, we generated an iPSC line from the cynomol-
gusmacaque with a homozygousMHCHT1 haplotype and
obtained iPSC-CM cell sheets in which approximately one
half of the cells were troponin T-positive CMs and the
remainder were vimentin-positive cells; CD31- or CD144-
positive cells were rarely identified. Because vimentin is
an intermediate filament expressed in mesenchymal cells
such as fibroblasts or endothelial cells, of which CD31
or CD144 is a marker, the vimentin-positive cells in
the iPSC-CMs might possibly represent fibroblasts. Using
the iPSC-CMs, we provided evidence of the efficacy of
MHC-matched allogeneic transplantation in a non-human
primatemodel. Under the same TAC,MMF, and PSL immu-
nosuppressive regimen, grafts in MHC-matched recipients
showed significantly increased numbers of engrafted iPSC-
CMs compared with those ofMHC-mismatched recipients.
Consistent with this, less severe infiltration of CD3+ and
CD4+ T cells, suggestive of less severe rejection, were
observed in MHC-matched recipients. However, all recipi-
ents regardless of MHC status exhibited severe rejection
without appropriate immunosuppressants. These findings
indicated that immunosuppressants in addition to TAC
might be required to prevent rejection in MHC-matched
iPSC-CM transplantation.
The efficacy and limitations of MHC-matched transplan-
tation are related to the role of MHC in allogeneic cell
Figure 3. Engraftment of Subcutane-
ously Transplanted iPSC-CMs
(A) Images of subcutaneously trans-
planted iPSC-CMs expressing GFP obtained
with a fluorescence stereomicroscope at
2 weeks, 1 month, and 2 months after
transplantation. Scale bar, 2 mm.
(B) Quantification of the fluorescence in-
tensity of GFP. Results are expressed as the
means ±SD for group I (nos. 1 and 2) and
group II (nos. 3–5). *p < 0.05.
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transplantation. Theoretically, the main mechanism of
MHC-matched transplantation is prevention of the host
immune reaction through MHC-restricted direct recogni-
tion for the donor cells as self by the recipient immuno-
competent cells, e.g., T cells. In general, approximately
1%–10% of naive T cells are activated by non-self MHC
molecules, but not by self MHC molecules via such a
‘‘direct pathway’’ (Janeway et al., 2001). Therefore, MHC-
matched transplantation might decrease the initial popu-
lation of T cells activated by transplanted cell MHCs
by recognizing them as self. In this study, the less severe
rejection effected by MHC-matched versus mismatched
iPSC-CM transplantation suggested that immune rejection
via the direct pathway might have been minimal in the
former. In addition, allogeneic iPSC-CMs caused severe
rejection in MHC-mismatched transplantation with com-
bined immune suppression within 1 month, even though
organ transplantation, including heart, lung, liver, and
kidney transplantations, is usually performed in an
MHC-mismatched manner without severe rejection under
the appropriate immunosuppression therapy. Therefore,
MHC-matched transplantation of iPSC-CMs represents a
promising approach for clinical applications to avoid
immunosuppression-related problems.
In contrast, MHC-matched transplantation might not
have substantial effects on the prevention of allogeneic
cell transplantation rejection in the indirect pathway, in
which the transplanted cell antigens are presented after
being phagocytosed and digested by recipient antigen-pre-
senting cells to activate recipient T cells, as observed in an-
imal 6 or 7. This might arise because the peptide antigens
would be derived from MHC proteins and other non-self
Figure 4. T Cell-Related Rejection of
Transplanted iPSC-CMs
(A) H&E, CD3, or CD4 staining of the
harvested iPSC-CM grafts 1 month after
transplantation. Scale bars, 500 mm (43),
100 mm (203).
(B) Semi-quantitative scoring of the num-
ber of CD3- or CD4-positive cells in the graft
1 month after transplantation. The results
are shown as the means ±SD for group I
(nos. 1 and 2) and group II (nos. 3–5).
*p < 0.05.
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peptides, acting asminor antigens. In this study,GFPmight
represent one of theminor antigens, as has previously been
reported (Stripecke et al., 1999), or non-peptide antigens
such as cell surface glycans, which have been reported to
be highly expressed in iPSC-CMs (Kawamura et al., 2014,
2015), might serve as well. The antigen causing rejection
inMHC-matched transplantationwill need to be identified
in further studies to overcome this limitation of allogeneic
iPSC-CM transplantation.
Rejection might also have occurred as iPSC-CMs might
fail to suppress recipient NK cells in MHC-matched trans-
plantation. MHC class I molecules such as MHC-E, which
are expressed on almost all cells in the body, bind to recep-
tors on NK cells to inhibit cytotoxic activity and, following
the immune reaction of NK cells (Janeway et al., 2001), are
recognized as self. Since the expression levels of MHC class
I genes in iPSC-CMswere low in this study, the graftsmight
have been recognized as non-self and rejected by recipient
NK cells. Consistent with this, MHC-matched transplanta-
tion using TAC only or without immune suppressants
induced elevated expression of the NK cell markers FcgR
III and NKG2D in the grafts (Figure S1E), which might
suggest that NK cell-related immune rejection might occur
during MHC-matched iPSC-CM transplantation if the
recipient did not receive appropriate immunosuppressants.
There were a few limitations to this study. The group
sizes in this study were very small, which limits statistical
robustness. In addition, we mainly performed subcutane-
ous transplantation of iPSC-CMs using silicone sheets to
evaluate engraftment and rejection by direct observation
of the transplanted iPSC-CMs and histological analysis of
the grafts. This might not be the optimal location or the
appropriate method as clinical applications would be ex-
pected to include transplantation to the heart without
foreign material, which could provoke the host inflamma-
tory response (Tang and Eaton, 1995) andmight havewors-
ened rejection. Notably, the iPSC-CMs transplanted into
the heart in this study exhibited poorer survival compared
with a previous report (Chong et al., 2014) in which
human embryonic stem cell-derived cardiomyocytes were
shown to survive for 3 months in the immune-suppressed
macaque. This discrepancy might be due to the difference
between the healthy heart in this study and themyocardial
infarction model in the study of Chong et al., or might
result from the different immunosuppressive regimens,
both of which are expected to have a significant influence
on the survival of transplanted cardiomyocytes. Further
study would be needed for the detailed evaluation of
immunological rejection and survival of the transplanted
iPSC-CMs in disease model hearts according to the clinical
applications.
In conclusion, the transplantation of MHC-matched
iPSC-CMs was effective for preventing allogeneic immune
rejection and allowing engraftment of transplanted cells
with appropriate immunosuppressants. The use of homo-
zygous MHC banked iPSC lines might be useful for future
regenerative therapy for a variety of pathologies.
EXPERIMENTAL PROCEDURES
Non-human Primates
Sevenmale cynomolgusmacaques (Ina Research) were used in this
study. Animal care procedures were consistent with the Guide for
the Care and Use of Laboratory Animals (NIH). Experimental proto-
cols were approved by the Ethics Review Committee for Animal
Experimentation of OsakaUniversityGraduate School ofMedicine
(reference no. 25-077-003).
Generation of iPSCs fromCynomolgusMacaques with
Homozygous MHC
We used the cynomolgus macaque iPSC line, 1123C1-G (a gift
from Professor Yamanaka), generated from an animal with a ho-
mozygous MHC haplotype as previously described (Okita et al.,
2013). iPSCs were cultured using AK02 medium (Ajinomoto) on
an LN511E8-coated (Nippi) dish as previously described (Miyazaki
et al., 2012; Nakagawa et al., 2014). The iPSCs were then trans-
fected with GFP as a donor cell marker as previously described
(Morizane et al., 2013).
Cardiomyogenic Differentiation of Macaque iPSCs
In Vitro
Cardiomyogenic differentiation of macaque iPSCs was performed
using a previously described protocol (Miki et al., 2015) with mod-
ifications (Figure 2A, Supplemental Experimental Procedures). On
day 12, the dish was incubated at room temperature, which
induced the cells to detach from the dish forming scaffold-free
iPSC-CM sheets.
Transplantation of iPSC-CMs
Transplantation was performed under general anesthesia, with
intubation and ventilation using sevoflurane. Macaque iPSC-CM
sheets, made from 3.3 3 106 cells per sheet, were subcutaneously
transplanted into the backs of recipient animals (three sheets per
animal). A 0.5-mm silicone sheet was placed on the iPSC-CM sheet
to prevent its adhesion to the skin for repeat observations (Figures
1B–1E). In addition, injection of the iPSC-CMs into the heart was
performed for animal 2, 4, and 5. The heart was exposed through
left thoracotomy and iPSC-CMaggregations in PBS (approximately
3.3 3 106 cells) were delivered intramyocardially into the anterior
wall of the left ventricle using an 18G needle. Needle tips were
placed within a preformed mattress suture, which was closed to
facilitate cell retention before needle withdrawal.
Immune Suppression
Macaques were divided into four groups as follows (Figure 1A):
treated with TAC, MMF, and PSL; treated with TAC only; given
no immunosuppressants; and those with no HT1 alleles (MHC-
mismatched allogeneic transplantation model) treated with TAC,
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MMF, and PSL. Oral administration of 2 mg kg1 day1 TAC or
continuous infusion of 0.5 mg kg1 day1 TAC to the femoral
vein using an ALZET osmotic pump (DURECT Corp.) was per-
formed from 2 days before transplantation to maintain serum
trough levels at >10 ng ml1 until the end of the study. In addi-
tion, 40 mg kg1 day1 MMF and 1 mg kg1 day1 PSL were orally
administered to the appropriate groups from 2 days before the
transplantation until the end of the study. Drug dosages were
based on clinical uses, as previously reported (Kinugasa et al.,
2008; Song et al., 2014).
Quantitatively Observation of Transplanted iPSC-CMs
Transplanted iPSC-CM sheets were observed using a fluorescence
stereomicroscope (MVX-10, Olympus) with fixed excitation laser
intensity and identical exposure times. The GFP fluorescence in-
tensities in the iPSC-CM sheets were quantified using ImageJ soft-
ware as the green signal intensities standardized by subtracting the
vessel intensities as the background and multiplied by the area.
The GFP intensity correlation with cell number was confirmed
by observing the two-layer and one-layer sections of the cell sheet
on day 0 (Figure S4A).
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